Kawin Technology(688687) 财信证券·2024-10-24 02:39Investment Rating - The report maintains a "Buy" rating for the company, with a target price range of 31.50 to 36.75 CNY per share based on a projected PE ratio of 30-35 times for 2025 [6][9]. Core Insights - The company has shown a significant decrease in sales expense ratio, which has driven rapid profit growth. For the first three quarters of 2024, the company achieved operating revenue of 1.011 billion CNY, a year-on-year increase of 0.82%, and a net profit attributable to shareholders of 108 million CNY, up 19.74% year-on-year [4]. - The company’s innovative biological product, Paiyisheng, has received acceptance for its listing application for treating chronic hepatitis B, which could create a second growth curve for the company. The potential market for chronic hepatitis B treatment in China is substantial, with approximately 20-30 million patients [5]. Financial Performance Summary - For 2024, the company is expected to achieve a net profit of 142 million CNY, with earnings per share (EPS) projected at 0.83 CNY. The compound annual growth rate (CAGR) for profit over the next three years is anticipated to exceed 20% [5]. - The company’s operating revenue is forecasted to grow from 11.60 billion CNY in 2022 to 21.17 billion CNY by 2026, with net profit increasing from 830 million CNY to 2.32 billion CNY over the same period [7]. - The gross profit margin for Q3 2024 was reported at 80.53%, with a net profit margin of 17.11%, reflecting a year-on-year increase of 3.41 percentage points [4]. Market Comparison - As of October 22, 2024, the company’s market capitalization stands at approximately 4.954 billion CNY, with a current price of 28.97 CNY per share, within a 52-week price range of 19.44 to 37.62 CNY [1].